| scholarly article | Q13442814 |
| P50 | author | Don C Des Jarlais | Q59824152 |
| Jonathan Feelemyer | Q91296279 | ||
| David H Perlman | Q121315102 | ||
| P2860 | cites work | A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs | Q24629455 |
| Racial/ethnic disparities in HIV infection among people who inject drugs: an international systematic review and meta-analysis | Q26825842 | ||
| Towards combination HIV prevention for injection drug users: addressing addictophobia, apathy and inattention | Q27008531 | ||
| Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention | Q27014761 | ||
| Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review | Q28295247 | ||
| Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: a systematic review | Q28297302 | ||
| Estimating the number of persons who inject drugs in the united states by meta-analysis to calculate national rates of HIV and hepatitis C virus infections | Q28538968 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome | Q29620780 | ||
| AIDS and injecting drug use in the United Kingdom, 1987-1993: the policy response and the prevention of the epidemic | Q30416719 | ||
| The hepatitis C cascade of care: identifying priorities to improve clinical outcomes | Q33632459 | ||
| The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States | Q33892586 | ||
| The natural history of hepatitis C virus infection: host, viral, and environmental factors | Q33974693 | ||
| Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus | Q34044333 | ||
| HIV and HCV infection among injecting drug users. | Q34076996 | ||
| High-prevalence and high-estimated incidence of HIV infection among new injecting drug users in Estonia: need for large scale prevention programs | Q34079048 | ||
| The effectiveness of harm reduction in preventing HIV among injecting drug users | Q34118193 | ||
| Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study | Q34126545 | ||
| High coverage needle/syringe programs for people who inject drugs in low and middle income countries: a systematic review | Q34323367 | ||
| Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. | Q34344995 | ||
| The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users | Q34498633 | ||
| Will there be a vaccine to prevent HCV infection? | Q34781537 | ||
| Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness | Q34968558 | ||
| Estimates of HIV incidence among drug users in St. Petersburg, Russia: continued growth of a rapidly expanding epidemic. | Q35233606 | ||
| HIV infection during limited versus combined HIV prevention programs for IDUs in New York City: the importance of transmission behaviors | Q35659939 | ||
| The first and second decades of AIDS among injecting drug users | Q35979838 | ||
| Prevalence, distribution, and correlates of hepatitis C virus infection among homeless adults in Los Angeles | Q36005257 | ||
| Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users | Q36088744 | ||
| HIV among people who inject drugs in Central and Eastern Europe and Central Asia: a systematic review with implications for policy | Q36370253 | ||
| HIV infection among intravenous drug users: epidemiology and risk reduction. | Q36433344 | ||
| Global estimates of prevalence of HCV infection among injecting drug users. | Q36940143 | ||
| Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy | Q37042425 | ||
| HIV prevention for injecting drug users: the first 25 years and counting | Q37180030 | ||
| Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection | Q37202576 | ||
| Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals | Q37601315 | ||
| The impact of harm reduction on HIV and illicit drug use | Q37607124 | ||
| Transitions from injecting to non-injecting drug use: potential protection against HCV infection | Q37625564 | ||
| Combined HIV prevention, the New York City condom distribution program, and the evolution of safer sex behavior among persons who inject drugs in New York City | Q37626445 | ||
| "Every 'never' I ever said came true": transitions from opioid pills to heroin injecting | Q37652892 | ||
| Behavioural interventions for preventing hepatitis C infection in people who inject drugs: a global systematic review | Q37945954 | ||
| HIV treatment as prevention among injection drug users | Q37974038 | ||
| Current progress in development of hepatitis C virus vaccines. | Q38120201 | ||
| Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. | Q38123948 | ||
| Can hepatitis C virus infection be eradicated in people who inject drugs? | Q38182241 | ||
| Why is it so difficult to develop a hepatitis C virus preventive vaccine? | Q38211880 | ||
| An overview of hepatitis C vaccines | Q38226971 | ||
| Continuity and change within an HIV epidemic. Injecting drug users in New York City, 1984 through 1992. | Q39405131 | ||
| Hepatitis C prevalence among Australian injecting drug users in the 1970s and profiles of virus genotypes in the 1970s and 1990s | Q42999459 | ||
| Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men--New York City, 2005-2010. | Q43038865 | ||
| Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. | Q45423068 | ||
| Causes of death in patients with hepatitis B: a natural history cohort study in the United States | Q46104385 | ||
| Confronting the emerging epidemic of HCV infection among young injection drug users. | Q51847014 | ||
| A randomized trial of a hepatitis care coordination model in methadone maintenance treatment. | Q51867806 | ||
| The promotion and marketing of oxycontin: commercial triumph, public health tragedy. | Q55050608 | ||
| A certain fate: Spread of HIV among young injecting drug users in Manipur, North-East India | Q58125300 | ||
| Continuity and change within an HIV epidemic. Injecting drug users in New York City, 1984 through 1992 | Q58436684 | ||
| Harm reduction and control of HIV in IDUs in France | Q61602481 | ||
| Effectiveness of methadone treatment in reducing HIV risk behavior and HIV seroconversion among injecting drug users | Q73064643 | ||
| Continued high HIV-1 incidence in a vaccine trial preparatory cohort of injection drug users in Bangkok, Thailand | Q73682509 | ||
| High rates of HIV infection among injection drug users participating in needle exchange programs in Montreal: results of a cohort study | Q74010685 | ||
| "Informed altruism" and "partner restriction" in the reduction of HIV infection in injecting drug users entering detoxification treatment in New York City, 1990-2001 | Q75257774 | ||
| P433 | issue | 2-3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis C | Q154869 |
| Hepatitis C virus | Q708693 | ||
| P304 | page(s) | 198-205 | |
| P577 | publication date | 2015-06-15 | |
| P1433 | published in | Journal of Addictive Diseases | Q15766326 |
| P1476 | title | Can HIV and Hepatitis C Virus Infection be Eliminated Among Persons Who Inject Drugs? | |
| P478 | volume | 34 |
| Q89484338 | Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation |
| Q30238798 | Conceptualizing Care Continua: Lessons from HIV, Hepatitis C Virus, Tuberculosis and Implications for the Development of Improved Care and Prevention Continua |
| Q89536780 | Feasibility and Acceptability of an mHealth-Based Approach as an HIV Prevention Strategy Among People Who Use Drugs on Pre-Exposure Prophylaxis |
| Q55425578 | Integrated Models of Care for Individuals with Opioid Use Disorder: How Do We Prevent HIV and HCV? |
| Q34511438 | Prevalence of hepatitis C virus infection among HIV+ men who have sex with men: a systematic review and meta-analysis |
| Q36025521 | Providing ART to HIV Seropositive Persons Who Use Drugs: Progress in New York City, Prospects for "Ending the Epidemic" |
| Q49824510 | The Syndemic of Opioid Misuse, Overdose, HCV, and HIV: Structural-Level Causes and Interventions |
| Q54271923 | Trends in HIV Infection Among Persons Who Inject Drugs: United States and Puerto Rico, 2008-2013. |
Search more.